OncoWuXi Newsletter: June 2022

WuXi AppTec xenograft and syngeneic tumor models in rats and CD47-related in vitro assay platform
OncoWuXi Newsletter June 2022
← Return to Resources

Related Content

In recent years, bispecific antibodies (BsAbs) have emerged as a novel strategy in tumor immunotherapy. BsAbs combine two distinct antigen...

VIEW RESOURCE

WuXi AppTec provides integrated and cost-effective services for: Polyclonal and monoclonal antibodies Anti-drug antibodies (ADA), host cell protein (HCP) antibodies,...

VIEW RESOURCE
← View all Antibodies Resources
× peptide, amino acid

Contact An Expert Today!